Answers are grounded in this paper and cite their sources.
Shows that TGFBR1 and TGFBR2 mutations cause aggressive vascular disease, indicating genotyping can guide timing of prophylactic surgery.
Mutations in either TGFBR1 or TGFBR2 predispose patients to aggressive and widespread vascular disease. The severity of the clinical presentation is predictive of the outcome. Genotyping of patients presenting with symptoms like those of vascular Ehlers-Danlos syndrome may be used to guide therapy, including the use and timing of prophylactic vascular surgery.
No takes yet. Share an insight, caveat, or question.
Loeys et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: